» Articles » PMID: 33924637

Prognostic Value of Bioactive Adrenomedullin in Critically Ill Patients with COVID-19 in Germany: An Observational Cohort Study

Overview
Journal J Clin Med
Specialty General Medicine
Date 2021 Apr 30
PMID 33924637
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The coronavirus disease 2019 (COVID-19) pandemic has placed a significant burden on hospitals worldwide. Objective biomarkers for early risk stratification and clinical management are still lacking. The aim of this work was to determine whether bioactive adrenomedullin can assist in the risk stratification and clinical management of critically ill COVID-19 patients. Fifty-three patients with confirmed COVID-19 were included in this prospective observational cohort study between March and April 2020. Bioactive adrenomedullin (bio-ADM) plasma concentration was measured daily for seven days after admission. The prognostic value and clinical significance of bio-ADM plasma levels were evaluated for the severity of respiratory failure, the need for extracorporeal organ support and outcome (28-day mortality). Bio-ADM levels increased with the severity of acute respiratory distress syndrome (ARDS; < 0.001) and were significantly elevated in invasively ventilated patients ( = 0.006) and patients in need of extracorporeal membrane oxygenation ( = 0.040) or renal replacement therapy (RRT; < 0.001) compared to patients without these conditions. Non-survivors showed significantly higher bio-ADM levels than survivors ( = 0.010). Bio-ADM levels predicted 28-day mortality (C-index 0.72, 95% confidence interval 0.56-0.87, < 0.001). Bio-ADM plasma levels correlate with disease severity, the need for extracorporeal organ assistance, and outcome, and highlight the promising value of bio-ADM in the early risk stratification and management of patients with COVID-19.

Citing Articles

Plasma bioactive adrenomedullin predicts mortality and need for dialysis in critical COVID-19.

Johnsson P, Sievert T, Didriksson I, Friberg H, Frigyesi A Sci Rep. 2024; 14(1):23787.

PMID: 39394248 PMC: 11470140. DOI: 10.1038/s41598-024-74380-x.


The Role of SARS-CoV-2 Nucleocapsidic Antigen and Krebs von den Lungen 6 Serum Levels in Predicting COVID-19 Pneumonia Outcome.

Sanduzzi Zamparelli S, Fucci V, Rea G, Perna F, Bocchino M, Sanduzzi Zamparelli A Diagnostics (Basel). 2024; 14(6).

PMID: 38535062 PMC: 10969613. DOI: 10.3390/diagnostics14060642.


Bioactive adrenomedullin and interleukin-6 in COVID-19: potential biomarkers of acute kidney injury and critical illness.

Leininger S, Staudner S, Vogel M, Mustroph J, Hubauer U, Wallner S BMC Nephrol. 2024; 25(1):52.

PMID: 38336628 PMC: 10858491. DOI: 10.1186/s12882-024-03486-1.


A Potential Association between Ribonuclease 1 Dynamics in the Blood and the Outcome in COVID-19 Patients.

Zechendorf E, Beckers C, Frank N, Kraemer S, Neu C, Breuer T Int J Mol Sci. 2023; 24(15).

PMID: 37569802 PMC: 10419077. DOI: 10.3390/ijms241512428.


Endotheliopathy in Acute COVID-19 and Long COVID.

Vassiliou A, Vrettou C, Keskinidou C, Dimopoulou I, Kotanidou A, Orfanos S Int J Mol Sci. 2023; 24(9).

PMID: 37175942 PMC: 10179170. DOI: 10.3390/ijms24098237.


References
1.
Murthy S, Gomersall C, Fowler R . Care for Critically Ill Patients With COVID-19. JAMA. 2020; 323(15):1499-1500. DOI: 10.1001/jama.2020.3633. View

2.
Dreher M, Kersten A, Bickenbach J, Balfanz P, Hartmann B, Cornelissen C . The Characteristics of 50 Hospitalized COVID-19 Patients With and Without ARDS. Dtsch Arztebl Int. 2020; 117(16):271-278. PMC: 7171478. DOI: 10.3238/arztebl.2020.0271. View

3.
Mebazaa A, Geven C, Hollinger A, Wittebole X, Chousterman B, Blet A . Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study. Crit Care. 2018; 22(1):354. PMC: 6305573. DOI: 10.1186/s13054-018-2243-2. View

4.
Paulus P, Jennewein C, Zacharowski K . Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis?. Biomarkers. 2011; 16 Suppl 1:S11-21. DOI: 10.3109/1354750X.2011.587893. View

5.
Tolppanen H, Rivas-Lasarte M, Lassus J, Sans-Rosello J, Hartmann O, Lindholm M . Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock. Ann Intensive Care. 2017; 7(1):6. PMC: 5209311. DOI: 10.1186/s13613-016-0229-2. View